May 2023 | Issue 69
www.cardiovascularnews.com
The best durability. CoreValve™/Evolut™ TAVR is the first and only platform to demonstrate a durability benefit over SAVR at five years in randomized clinical trials.†1 Bioprosthetic valve dysfunction out to 5 years
20%
BVD cumulative incidence
Surgery (N = 971) 15%
14.2%
CoreValve/Evolut TAVR (N = 1,128) P < 0.001
10%
7.8%
5%
0%
0
1
2
3
Years post-procedure
4
Significantly better valve performance‡ versus SAVR at five years.
5
CoreValve 88%, Evolut R 12% Fine-Gray P value
* †
3x lower severe PPM versus SAVR at 30-day/discharge.
3.7%
CoreValve/Evolut TAVR
11.8%
SAVR
p < 0.001
See important safety information on page 2. TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker. † ‡
In pooled analysis of intermediate- and high-risk patients. Devices used: CoreValve 88%/Evolut R 12%. Bioprosthetic Valve Dysfunction (BVD) was defi ned as 2,3: SVD4 (mean gradient ≥ 10 mm Hg increase from discharge/30 days AND ≥ 20 mm Hg at last echo or new onset/increase of ≥ moderate intraprosthetic aortic regurgitation), NSVD (30-day severe PPM at 30-day/discharge2 or severe PVR through 5 years), clinical valve thrombosis, and endocarditis.